Phosphoglycerate kinase 1 inhibitor / Inhibitor of Cdc2-cyclin B (IC50 = 340 nM) as well as Cdc28p (IC50 = 7 µM) and Pho85p (IC50 = 2 µM).1 It inhibited phosphoglycerate kinase 1 (IC50 = 2.5 µM) and inhibited the proliferation of glioma U87 and U251 cell lines via reversal of the Warburg effect.2 NG52 inhibited the proliferation, increased apoptosis, and reduced the migration and invasive ability of OVCAR3 and ES-2 ovarian cancer cell lines via suppression of glycolytic capability.3
Biochemicals & reagents
212779-48-1
1) Gray et al. (1998), Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors; Science, 281 533 2) Wang et al. (2021), Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52; Acta Pharmacol. Sin., 42 633 3) Gou et al. (2021), PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes; Front. Oncol., 11 682461
-20°C
TARGET: Kinase -- PATHWAY: Cell cycle; Warburg effect; Proliferation; Cell migration -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer